Price
$0.075
Increased by 0.00%
Dollar Volume
2.24 M
ADR%
86.11
Earnings Report Date (estimate)
Nov 8, 22 (-0.06)
Market Cap.
9.16 M
Shares Float
120.96 M
Shares Outstanding
122.08 M
Beta
1.15
Price / Earnings
0.00
BPR
12.82
20D Range
0.02 0.22
50D Range
0.02 0.33
200D Range
0.02 0.77
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 16, 22 -0.13
Increased by +38.10%
-0.14
Increased by +7.14%
Mar 31, 22 -0.11
Increased by +54.17%
-0.16
Increased by +31.25%
Nov 10, 21 -0.17
Increased by +22.73%
-0.18
Increased by +5.56%
Aug 10, 21 -0.24
Increased by +7.69%
-0.21
Decreased by -14.29%
May 11, 21 -0.21
Increased by +32.26%
-0.23
Increased by +8.70%
Mar 9, 21 -0.24
Increased by +48.94%
-0.19
Decreased by -26.32%
Nov 9, 20 -0.22
Increased by +61.40%
-0.21
Decreased by -4.76%
Aug 5, 20 -0.26
Increased by +51.85%
-0.30
Increased by +13.33%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 22 0.00
Decreased by N/A%
-8.44 M
Increased by +39.63%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-11.81 M
Decreased by -1.52%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
5.46 M
Increased by +153.18%
Increased by +N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-12.69 M
Decreased by -58.14%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-13.97 M
Decreased by -100.29%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-11.64 M
Decreased by -53.41%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-10.26 M
Increased by +9.69%
Decreased by N/A%
Decreased by N/A%
Sep 30, 20 0.00
Decreased by N/A%
-8.03 M
Increased by +39.60%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.